Compare GD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GD | VRTX |
|---|---|---|
| Founded | 2019 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.1B | 115.7B |
| IPO Year | 2006 | 2006 |
| Metric | GD | VRTX |
|---|---|---|
| Price | $339.61 | $444.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 29 |
| Target Price | $375.33 | ★ $539.69 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | 13.35 | ★ 836.54 |
| EPS | ★ 15.45 | 15.32 |
| Revenue | ★ $52,550,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $7.30 | $10.81 |
| Revenue Next Year | $4.49 | $10.41 |
| P/E Ratio | ★ $22.03 | $28.74 |
| Revenue Growth | 10.13 | ★ 46.20 |
| 52 Week Low | $262.84 | $362.50 |
| 52 Week High | $369.70 | $510.77 |
| Indicator | GD | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 46.35 |
| Support Level | $337.16 | $427.52 |
| Resistance Level | $348.37 | $467.86 |
| Average True Range (ATR) | 7.22 | 10.92 |
| MACD | -0.93 | 0.45 |
| Stochastic Oscillator | 28.95 | 56.89 |
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments are aerospace, marine, combat systems, and technologies. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear-powered submarines, destroyers, and Navy support ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business focusing on electronics that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.